Higashino Masaaki, Kawata Ryo, Lee Koutetsu, Nishikawa Shuji, Ichihara Shimpei, Uesugi Yasuo
Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.
Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.
Auris Nasus Larynx. 2014 Aug;41(4):364-8. doi: 10.1016/j.anl.2014.02.001. Epub 2014 Mar 20.
We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium).
In T2N0 glottic carcinoma patients, we retrospectively compared the local control rate and outpatient therapy completion rate between 20 patients who received radiotherapy plus S-1 (S-1 group) and 20 who received radiotherapy alone (RT group).
Local recurrence was not detected in any of the 20 subjects from the S-1 group, whereas local recurrence was found in 4 of the 20 subjects (20%) from the RT group (p<0.05). Outpatient treatment was completed by 15 of the 20 subjects from the S-1 group and 17 of the 20 subjects from the RT group (p=0.43).
We investigated chemoradiotherapy with S-1 in patients who had T2N0 glottic carcinoma and found a higher local control rate when compared with radiotherapy alone as well as comparable safety for outpatient delivery.
我们研究了接受S-1（替吉奥，即替加氟-吉美嘧啶-奥替拉西钾）同步放化疗的T2N0声门癌患者的完成率、安全性和不良事件。
在T2N0声门癌患者中，我们回顾性比较了20例接受放疗加S-1的患者（S-1组）和20例单纯接受放疗的患者（RT组）的局部控制率和门诊治疗完成率。
S-1组的20例患者中均未检测到局部复发，而RT组的20例患者中有4例（20%）出现局部复发（p<0.05）。S-1组的20例患者中有15例完成了门诊治疗，RT组的20例患者中有17例完成了门诊治疗（p=0.43）。
我们研究了S-1同步放化疗用于T2N0声门癌患者的情况，发现与单纯放疗相比，其局部控制率更高，且门诊治疗的安全性相当。
